PCM
NVO

Palouse Capital Management’s Novo Nordisk NVO Stock Holding History

Palouse Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,000
Closed -$257K – 144
2024
Q1 		$257K Buy
+2,000
New +$238K 0.17% 62

Other funds holding NVO

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Palouse Capital Management's NVO Position: Q2 2024 in Review

Palouse Capital Management sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 2,000 shares — an estimated $257K sold.

Palouse Capital Management first reported a position in NVO in Q1 2024 and held it in 1 quarter. The position peaked at $257K in Q1 2024. 1,861 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Palouse Capital Management reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
  • Palouse Capital Management sold 2,000 Novo Nordisk shares in Q2 2024, an estimated $257K.
  • Palouse Capital Management first reported a position in Novo Nordisk in Q1 2024 and held it in 1 quarter.
  • Palouse Capital Management's Novo Nordisk position peaked at $257K in Q1 2024.
  • 1,861 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Palouse Capital Management's 13F filing for Q2 2024, filed 12 Aug 2024.